Detalhe da pesquisa
1.
Reduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistance.
EMBO J
; 41(8): e108272, 2022 04 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35211994
2.
Non-synonymous, synonymous, and non-coding nucleotide variants contribute to recurrently altered biological processes during retinoblastoma progression.
Genes Chromosomes Cancer
; 62(5): 275-289, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36550020
3.
The O6-methyguanine-DNA methyltransferase inhibitor O6-benzylguanine enhanced activity of temozolomide + irinotecan against models of high-risk neuroblastoma.
Anticancer Drugs
; 32(3): 233-247, 2021 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33323683
4.
Vorinostat and fenretinide synergize in preclinical models of T-cell lymphoid malignancies.
Anticancer Drugs
; 32(1): 34-43, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33079733
5.
Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia.
Anticancer Drugs
; 30(2): 117-127, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30272587
6.
Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program.
Pediatr Blood Cancer
; 65(2)2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28921800
7.
Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines.
Pediatr Blood Cancer
; 65(12): e27447, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30251395
8.
Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.
Pediatr Blood Cancer
; 65(7): e27023, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29603591
9.
P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models.
Int J Cancer
; 141(2): 405-413, 2017 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28340497
10.
Microfluidic Separation of Lymphoblasts for the Isolation of Acute Lymphoblastic Leukemia Using the Human Transferrin Receptor as a Capture Target.
Anal Chem
; 89(14): 7340-7347, 2017 07 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-28656755
11.
Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.
Pediatr Blood Cancer
; 64(4)2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27786412
12.
Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.
Pediatr Blood Cancer
; 64(4)2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27650817
13.
Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program.
Pediatr Blood Cancer
; 63(3): 443-50, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26797892
14.
Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.
Pediatr Blood Cancer
; 63(10): 1744-52, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27238606
15.
Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.
Pediatr Blood Cancer
; 63(2): 276-86, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26398108
16.
Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration.
Exp Cell Res
; 334(1): 78-89, 2015 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25845499
17.
Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.
Cancer Immunol Immunother
; 64(5): 621-34, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25711293
18.
Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.
Pediatr Blood Cancer
; 62(11): 1897-905, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26154614
19.
Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.
Pediatr Blood Cancer
; 62(1): 91-8, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25263539
20.
Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program.
Pediatr Blood Cancer
; 62(6): 1106-9, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25407467